Pfizer, the world's largest drug maker, told more than 100 trial investigators to stop giving patients the drug, called torcetrapib. The drug was intended to treat heart disease, but it actually ...

Small mean decrease of 9% in triglycerides compared with baseline (all P <.001 vs atorvastatin only). These lipid effects were consistent with those in previous studies. However, the primary endpoint ...

Data slated for release Monday could shed light on Pfizer’s torcetrapib failure and help determine the fate of other compounds in the same class.The data, from two carotid IMT trials run by a ...

Presenting the ILLUMINATE data, Dr Philip Barter (Heart Research Institute, Sydney, Australia) commented: "There have been concerns voiced that the HDL produced by CETP inhibitors may be dysfunctional ...

Dec. 5, 2006 &#151; -- It was supposed to be the next cholesterol wonder drug. Many hoped its impact would be revolutionary, on par with cholesterol-busting statins in its lifesaving potential. Now, ...

A Pfizer analysis released this week brought new hope to a class of drugs designed to clear arteries by boosting the protective form of cholesterol. The findings could help firms like Roche and Merck ...

On Saturday morning, Pfizer's rookie CEO and former general counsel Jeffrey Kindler was at his Connecticut home preparing to make pancakes for his daughter's 18th birthday when he received some grim ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Pfizer has terminated its Lipid Level Management to ...

Please provide your email address to receive an email when new articles are posted on . An analysis of the ILLUMINATE trial data revealed new findings: Torcetrapib, a cholesteryl ester transfer ...

There's lots of anticipation building for the ACC meeting in New Orleans. One of the most closely-watched presentations will detail how torcetrapib failed a trial that experts in the field had widely ...

A new study on the Pfizer drug torcetrapib found that it does not slow plaque buildup in the coronary arteries, despite raising by more than 60% the levels of high-density lipoprotein cholesterol, the ...

Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a potent CETP inhibitor, might ...